Dr. Kyung Won Seo is the Director General of the National Institute of Food and Drug Safety Evaluation at the Ministiry of Food and Drug Safety Korea since February 2021. Dr. Seo has involved in many toxicological research and studies and reviewed non-clinical data for 15 years. Dr. Seo was in charge of several divisions as Director including metabolic, reproductive and respiratory product; antibiotics and oncology product; and bioequivalence evaluation. Prior to her current position, Dr. Seo served as Director General of Pharmaceutical and Medical Device Research Department from 2015 to 2019.

Gerald J. Dal Pan, MD, MHS currently serves as the Director of the Office of Surveillance and Epidemiology in FDA’s Center for Drug Evaluation and Research, where since 2005 he has been responsible for the Center’s programs in adverse event surveillance and analysis, pharmacoepidemiology, risk management, and medication error prevention. In this capacity, he is involved in both the premarket and postmarket regulation of drugs and therapeutic biologics, and in the implementation of the drug safety provisions of the Food and Drug Administration Amendments Act and other initiatives.

Rie Matsui is Senior Director, Regional Labeling Head for APAC, International Labeling Group, Global Regulatory Science, Pfizer Japan. She is also the Head, External Engagements for ILG. She is the founder of Asia Labeling Hub at Pfizer that has created various local label updates for more than 25 countries in Asia. She was a member of the Advisory Council of DIA Japan until 2020 and received the DIA Japan regional award in 2015. Her papers were published in scientific journals such as Therapeutic Innovation & Regulatory Science. She is the vice chair of the 2021 DIA Japan Annual Meeting Program Committee. She received DIA Global Inspire Award Connector in 2022. She is teaching at Keio University and Chiba University and is a pharmacist.

Dr. Mohit Raizada is the Director and Head of Signal Management Services in the Lifecycle Safety department at IQVIA, India. He is an expert in signal management and has successfully onboarded, led, executed, and completed complex signal management projects for various companies. Mohit is currently leading the India Signal Management team and providing expert consulting on Signal Management projects for numerous companies, involving over 1000 marketed products. Mohit has 14 years of experience in Pharmacovigilance, including 10 years in Signal Management. He holds a bachelor's degree in dental surgery along with a Diploma in Clinical Research and Pharmacovigilance.

SangHee Kim is the Global Head of Centralized Monitoring & RBQM at Novotech. With over 30 years of experience in pharma (Sanofi) and CROs (Novotech), she has led clinical trial management, pharmacovigilance, and medical affairs. She holds a Pharmacy degree from ChungAng University and a PhD in Pharmacoepidemiology from SungKyunKwan University. She has also actively contributed to the clinical trial industry for over 15 years through KSCD.

Min-Jung Lim is the CEO and Senior Pharmacovigilance Consultant at MediSafe, with over 25 years of experience in clinical research and pharmacovigilance. She previously led drug safety functions as Head of Pharmacovigilance & Post Marketing Studies at GSK Korea. She also serves as an Adjunct Professor at CHA University and Head of the Pharmacovigilance Division of the Korea Clinical Development Association. A licensed pharmacist in Korea, Ms. Lim holds a Master’s degree in Pharmacology. She has supported numerous pharmaceutical companies and bio-ventures in PV system development and risk management. She is an organizer of national training programs for pharmacovigilance professionals across regulatory and academic settings.